 PALO ALTO, Calif. SHANGHAI PRINCETON, N.J.--BUSINESS WIRE--LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, and BridgeBio Pharma, Inc. Nasdaq: BBIO today announced the first patient has been treated in a Phase 2a clinical trial of infigratinib in patients with locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with fibroblast growth factor receptor-2 FGFR2 gene 